Rabelais BioSanté Pôle
The Rabelais BioSanté Pôle is a recognised authority for coordination between training and research in Biology and Health structures in Montpellier. Since its creation, Montpellier SIRIC has taken an active part in the dynamic development of the ‘Cancer axis’ and is a major player in one of the six themes of the Rabelais Pôle.
Grand Sud-Ouest (GSO) Canceropôle
The Grand Sud-Ouest (GSO) Canceropôle is one of the seven cancer centres accredited by the National Cancer Institute (INCa) as part of the overall Cancer Plan. With an inter-regional and multi-disciplinary approach, it brings together nearly 500 teams of researchers and clinicians, mobilised against cancer throughout the country – the Aquitaine team in Bordeaux, the Limousin team in Limoges, the Languedoc-Roussillon team in Montpellier and Nîmes and the Midi-Pyrenees team in Toulouse. The Canceropôle shares expertise and know-how in order to create and strengthen research projects, and to accelerate the transfer of therapeutic innovation for the benefit of patients.
Based on a partnership between the Universities of Tours and Montpellier, associated with INSERM, the CNRS, the INRA, the CHRU of Tours and Montpellier Cancer Institute, MAbImprove LabEx federates 13 research teams and more than 200 researchers. It is based on the complementarity of both sites, as well as on a national network of academic teams involved in the project and numerous pharmaceutical and biotechnology companies directly affected by fallout from the project. The MabImprove Labex aims to improve understanding of the pharmacology of monoclonal antibodies in humans.The purpose is to improve their use, improve their design and development and to develop the best.
The MAbImprove LabEx project is led by Prof. Hervé Watier (Tours coordinator) and Dr. André Pèlegrin (Montpellier deputy coordinator).
Eurobiomed leads territorial initiatives, provides resources and offers solutions for businesses and research organisations. Eurobiomed helps them innovate, finance, develop and achieve their strategic and business objectives to ultimately improve life through innovations in health.
Founded in 2009 by regional stakeholders, Eurobiomed tops European rankings in all stages of innovation: education, basic research, translational and clinical research, technological innovation centers, start-ups and industrial success stories.
Together, the +260 Eurobiomed members from about 220 differnet companies are a driving force in regional development (with 160 projects, representing 585 million euros of investment and 700 direct jobs) and a source of solutions for millions of patients coping with seroius conditions such as cancer, chronic inflammatory diseases, infectious and (re)emerging diseases, neurological diseases, and rare diseases.
Eurobiomed provides resources and offers solutions for businesses and research organisations in the health sector to help them innovate, finance, develop and achieve their strategic and business objectives to ultimately improve the treatment and the lives of patients.
The mission of the ONCO LR Network is to ensure coordination and the harmonisation of practices between different stakeholders involved in oncology in the Languedoc-Roussillon region. In particular the network undertakes the task of promoting improvements to the quality of cancerology and providing patients with information about the organisation of cancer care in Languedoc Roussillon.